HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.
Qinqin Zuo, Wenjing Wu, Xu Li, Le Zhao, Wei Chen
Index: Oncol. Rep. 27(3) , 819-24, (2012)
Full Text: HTML
Abstract
Histone deacetylase 6 (HDAC6) promotes cell motility and contributes to the metastasis of cancers. The purpose of this study was to investigate the role of HDAC6 in human bladder cancer for the first time. The results showed that HDAC6 promotes the migration and invasion of bladder cancer cells by targeting the cytoskeletal protein cortactin. Furthermore, a colony formation assay as well as in vitro migration and invasion assays demonstrated that this migration and invasion was suppressed by the HDAC6-specific inhibitor tubacin. In addition, cortactin is the substrate of SIRT2, which also belongs to the family of histone deacetylases. We demonstrated that by using SIRT2-specific siRNA combined with tubacin treatment, the cell migratory and invasive abilities were dramatically suppressed. Taken together, we conclude that HDAC6 and SIRT2 work synergistically to promote cell migration and invasion in bladder cancer, and the HDAC6-specific inhibitor tubacin may be regarded as a novel therapeutic agent for bladder cancer.
Related Compounds
Related Articles:
SMAR1 coordinates HDAC6-induced deacetylation of Ku70 and dictates cell fate upon irradiation.
2014-01-01
[Cell Death Dis. 5 , e1447, (2014)]
Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
2014-06-01
[Cancer Biol. Ther. 15(6) , 742-57, (2014)]
2014-12-15
[Cancer Res. 74(24) , 7475-86, (2014)]
Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2.
2015-05-01
[Cancer Res. 75 , 1868-82, (2015)]
2015-08-01
[Mol. Med. Report. 12 , 2661-7, (2015)]